Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Healthcare providers

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Healthcare providers. Displaying page 1 of 1.
    EudraCT Number: 2018-004588-30 Sponsor Protocol Number: D5180C00011 Start Date*: 2019-06-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector with Home-administered Subcutaneous Tezepelumab i...
    Medical condition: Severe uncontrolled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-006581-20 Sponsor Protocol Number: HEMCML28 Start Date*: 2022-05-11
    Sponsor Name:Radboud univeristy medical centre
    Full Title: A patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: a prospective, multi-centre, non-randomised non-inferiority study.
    Medical condition: Chronic myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024296 Leukaemias chronic myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002271-36 Sponsor Protocol Number: MEPIC Start Date*: 2021-03-09
    Sponsor Name:Danderyd Hospital
    Full Title: Mepivacaine for pain relief at insertion of intrauterine contraception (MEPIC) – a triple-blind randomized controlled trial.
    Medical condition: Insertion of intrauterine contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021425-13 Sponsor Protocol Number: 212082PCR3001 Start Date*: 2011-02-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (PCR)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) HU (Completed) ES (Completed) IT (Completed) LT (Prematurely Ended) DK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003712-23 Sponsor Protocol Number: CLAF237A23156 Start Date*: 2012-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) LV (Completed) IT (Completed) HU (Completed) DE (Completed) EE (Completed) SK (Completed) BG (Completed) PL (Completed) NO (Completed) CZ (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005483-10 Sponsor Protocol Number: DPIP-2012-02 Start Date*: 2013-05-01
    Sponsor Name:University College Dublin
    Full Title: Dipeptidyl peptidase-4 Inhibition and Narrow-band Ultraviolet-B light in Psoriasis (DINUP): A Randomised Clinical Trial.
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005505-51 Sponsor Protocol Number: DPIDM-2012-01 Start Date*: 2013-05-01
    Sponsor Name:University College Dublin
    Full Title: Dipeptidyl peptidase-4 Inhibition in Psoriasis patients with diabetes (DIP): A Randomized Clinical Trial.
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003466-39 Sponsor Protocol Number: Protocol_MAMA_studie_22/05/2018 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Antwerp
    Full Title: Pertussis immunization during pregnancy: assessment of the role of maternal antibodies on immune responses in term and preterm infants (the MAMA study)
    Medical condition: The effect of pertussis vaccination during pregnancy on the immune response after infant and childhood vaccinations in term and preterm infants.
    Disease:
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002538-14 Sponsor Protocol Number: 218672 Start Date*: 2023-06-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: 17-beta-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003397-32 Sponsor Protocol Number: MK2140-004 Start Date*: 2021-12-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Medical condition: Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) EE (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000219-18 Sponsor Protocol Number: PsiloRCT001 Start Date*: 2018-04-09
    Sponsor Name:Imperial College London
    Full Title: Psilocybin vs. escitalopram for major depressive disorder: comparative mechanisms
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000660-33 Sponsor Protocol Number: ZAF-312 Start Date*: 2015-09-30
    Sponsor Name:Zafgen Inc.
    Full Title: Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of Beloranib in Obese Subjects with Prader-Willi Syndrome to Evaluate Food-related Behavior, Total Body Weight, and Safety Over 52 Weeks
    Medical condition: Improvement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000855-35 Sponsor Protocol Number: HZNP-DAX-204 Start Date*: 2022-09-23
    Sponsor Name:Horizon Therapeutics Ireland DAC
    Full Title: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003313-18 Sponsor Protocol Number: MK-2140-003 Start Date*: 2022-01-10
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Larg...
    Medical condition: Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005528-12 Sponsor Protocol Number: VIB7734.P2.S1 Start Date*: 2021-08-17
    Sponsor Name:Viela Bio, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-004092-31 Sponsor Protocol Number: I6T-MC-AMAP Start Date*: 2018-06-25
    Sponsor Name:Eli Lilly and Company
    Full Title: I6T-MC-AMAP A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long- Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (LU...
    Medical condition: moderately to severely active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) LV (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) DE (Completed) ES (Ongoing) AT (Trial now transitioned) SK (Trial now transitioned) HR (Prematurely Ended) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005067-32 Sponsor Protocol Number: I4T-MC-JVCZ Start Date*: 2015-11-24
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I4T-MC-JVCZ Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination with Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gast...
    Medical condition: Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SE (Completed) GR (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003925-26 Sponsor Protocol Number: 28156 Start Date*: 2008-01-24
    Sponsor Name:Merck Serono International S.A.
    Full Title: Estudio aleatorizado, multicéntrico, doble ciego, de dos ramas y controlado frente a placebo para evaluar la seguridad y la tolerabilidad, y para explorar el efecto neuroprotector de atacicept eva...
    Medical condition: Neuritis óptica Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) BE (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 05:01:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA